Status:
COMPLETED
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. Thi...
Eligibility Criteria
Inclusion
- Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months.
- Has HbA1c of 7.1% to 11.0%, inclusive.
- Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.
Exclusion
- Received any investigational drug within 3 months prior to screening.
- Is currently treated with any of the following excluded medications: \*Thiazolidinediones within 3 months of screening; \* Sulfonylureas within 3 months of screening; \* Insulin within 1 year of screening.
- Participated previously in an exenatide clinical study.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00103935
Start Date
February 1 2005
End Date
October 1 2005
Last Update
February 24 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Walnut Creek, California, United States
2
Research Site
Honolulu, Hawaii, United States
3
Research Site
St Louis, Missouri, United States
4
Research Site
Butte, Montana, United States